NASDAQ:ADGM • US00534B1008
The current stock price of ADGM is 1 USD. In the past month the price increased by 13.78%. In the past year, price decreased by -22.48%.
ChartMill assigns a technical rating of 4 / 10 to ADGM. When comparing the yearly performance of all stocks, ADGM turns out to be only a medium performer in the overall market: it outperformed 49.05% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to ADGM. ADGM may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ADGM reported a non-GAAP Earnings per Share(EPS) of -4.75. The EPS decreased by -229.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -250.89% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
7 analysts have analysed ADGM and the average price target is 4.08 USD. This implies a price increase of 308% is expected in the next year compared to the current price of 1.
For the next year, analysts expect an EPS growth of 65.5% and a revenue growth -100% for ADGM
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.41 | 197.518B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.82 | 175.875B | ||
| SYK | STRYKER CORP | 24.2 | 139.086B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.16 | 108.957B | ||
| IDXX | IDEXX LABORATORIES INC | 41.66 | 51.801B | ||
| BDX | BECTON DICKINSON AND CO | 11.28 | 51.46B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.71 | 46.035B | ||
| RMD | RESMED INC | 20.01 | 37.897B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.66 | 36.095B | ||
| DXCM | DEXCOM INC | 25.78 | 26.58B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Adagio Medical Holdings, Inc. is a medical device company, which engages in the development ablation technologies for the treatment of cardiac arrhythmias. The company is headquartered in Laguna Hills, California and currently employs 86 full-time employees. The company went IPO on 2021-02-26. The company is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. The company is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.
ADAGIO MEDICAL HOLDINGS INC
26051 Merit Circle, Suite 102
Laguna Hills CALIFORNIA US
Employees: 86
Phone: 19493481188
Adagio Medical Holdings, Inc. is a medical device company, which engages in the development ablation technologies for the treatment of cardiac arrhythmias. The company is headquartered in Laguna Hills, California and currently employs 86 full-time employees. The company went IPO on 2021-02-26. The company is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. The company is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.
The current stock price of ADGM is 1 USD. The price decreased by -0.99% in the last trading session.
ADGM does not pay a dividend.
ADGM has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
ADAGIO MEDICAL HOLDINGS INC (ADGM) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
ADAGIO MEDICAL HOLDINGS INC (ADGM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.75).
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADGM.